BPC-157 TB-500 dosage, as studied — not as prescribed

BPC-157 and TB-500 Dose Ranges in Preclinical Studies

BPC-157 TB-500 dosage has no validated value for the blend. The figures below come from single-compound animal studies and describe what was administered to which species by which route — they are not human guidance and do not translate to a blend dose. The framing throughout this page is deliberate: "studied at X in [species] by [route]," never "take X."

The BPC-157 component, in rodent models, is commonly expressed per body weight, frequently around 10 microg/kg and 10 ng/kg; gastric-ulcer cytoprotection was studied at 400-800 ng/kg in rats ^[1]. Expressing a dose per kilogram of body weight is how animal pharmacology works, and it is precisely why those numbers cannot be lifted into a fixed human milligram amount. The TB-500 / Thymosin Beta-4 component spans a far wider range: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study (modeled optimum ~3.75 mg/kg, while 18 mg/kg gave no benefit — higher was not better), and 150 microg twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study ^[4]. That non-monotonic result — a high dose performing worse than a middle one — is the single most useful caution on this page, because it directly contradicts the loading logic behind many community blend protocols.

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated in Phase 1 work ^[4]. Commercial vials commonly pair fixed combined masses (e.g. ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study exists, and the fixed-mass label is a packaging convention, not a validated dose ^[1].

Routes, Half-Life, and Handling in the Research

The routes the research used are not the routes the community uses, and the distinction matters for anyone reading vendor protocols. The underlying rodent efficacy studies for both peptides were predominantly intraperitoneal; human Phase 1 data for full-length Thymosin Beta-4 and a BPC-157 safety pilot used intravenous routes ^[1][4]. Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but they do not come from controlled human efficacy trials.